Bioheart Inc, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.
Approximately four years ago in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell(TM)) in congestive heart failure patients. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.
This fat was processed to obtain the stromal vascular fraction (SVF) which
James Eilert went on a 20-mile bike ride the other day! Why is that amazing?
Because18 months ago, the thought of getting on a bicycle was too much exertion for the Michigan native. In 2006, at the young age of 34, James suffered a major heart attack, which damaged his heart muscle.
The heart damage left James fatigued, exhausted and short of breath. It was increasingly difficult to meet the demands of his job as an automotive engineer. He was gasping for breath and sweating all the time. His ejection fraction (EF) had sunk to 20-25%. Feeling depressed,
(…) Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells, that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials. The REGEN trial is designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein. The SDF-1 protein is a molecule in the human body that, after an injury, is naturally released by most tissues to attract stem cells. The stem cells assist with the healing process.
Image via CrunchBase
Stemedica Cell Technologies, Inc. announced today that its strategic partner in Mexico, Grupo Angeles Health Services, has received approval from Mexico’s regulatory agency, COFEPRIS, for a Phase I/II single-blind randomized clinical trial for chronic heart failure. COFEPRIS is the Mexican equivalent of the United States FDA. The clinical trial, to be conducted at multiple hospital sites throughout Mexico, will utilize Stemedica’s adult allogeneic ischemia tolerant mesenchymal stem cells (itMSC) delivered via intravenous infusion. The trial will involve three safety cohorts at different dosages, followed by a larger group being treated with the maximum safe dosage. The
Stem Cell Research Trials for Heart Attacks and Heart Failure
Recent stem cell research studies using Adult Stem Cells to treat heart diseases such as congestive heart failure and heart attacks have made the news recently. And on the surface, these adult stem cell success stories of heart attack victims making amazing recoveries in these research […]